TrialData Exchange
Where intelligence, capital, and clinical trials converge.
One platform from protocol authoring to autonomous monitoring — adaptive design, predictive enrollment, regulatory automation, and a tokenized data marketplace, composed as one operating system.
Enrolled
Sites
Power
Enrollment · 60-day forecast
+24 projected
ADAPT — Enrichment recommended
Subgroup B response > prior. Margin 8.4%. Confidence 0.92.
Interim analysis complete
DSMB notification dispatched · 8 sites
Site 14 · enrollment hold lifted
IRB approval received
Protocol amendment #3 drafted
Pending regulatory review
Adaptive Intelligence Engine
Illustrative
The problem
$2.6B and 12 years for one drug.
The clinical-trial industry runs on infrastructure built decades ago. Disconnected tools, manual workflows, and data that never gets reused. We're rebuilding the layer underneath.
80%
of trials face enrollment delays
37%
of sites miss enrollment targets
$40B
in clinical data unused every year
Most trial software was built for the regulatory era of 2005, not the adaptive, decentralized, data-rich era of 2026.
Inside the platform
What it looks like in practice.
Three views from real workflows — adaptive monitoring, regulatory gap analysis, and the trial-to-token marketplace.
Illustrative · platform views
Regulatory gap analysis
PROT-IND-0042
Section
FDA
EMA
ICH
Statistical analysis plan
✓
✓
✓
Risk-based monitoring
✓
✓
—
Pediatric investigation
—
Gap
—
DSUR / annual report
✓
Gap
✓
Adaptive design notice
Draft
✓
✓
Regulatory copilot
2 gaps detected
Enrollment forecast
On trackPredicted finish: Q3 2026
Velocity
+3.4 / week
Dropout risk
8.2%
Enrollment Intelligence
T2T Marketplace
3 listings
DATA-4287
$84k
Oncology · NSCLC
412 pts · provenance verified
+12%
DATA-4291
$52k
Neurology · MCI
228 pts · provenance verified
+4%
DATA-4302
$140k
Cardiology · HF
640 pts · provenance verified
+18%
Trial-to-Token
On-chain provenance
The ecosystem
One platform. Seven constituencies.
Modern clinical trials don't happen inside one organization. TrialDataX.AI is built for the people who design them, run them, participate in them, fund them, regulate them, and validate them.
The platform doesn't pick a side of the table — it sits at the center of all of them.
Ecosystem · network view
Seven nodes
Sits at the center
01
Sponsors
Pharma · biotech
02
CROs
Trial operations
03
Research sites
Hospitals · academic centers
04
Patients
Participants · communities
05
Regulators
FDA · EMA · ICH
06
Academia
Investigators · KOLs
07
Capital
Life-science investors
Capabilities
Eight integrated engines.
From protocol design and patient intelligence to autonomous monitoring and a tokenized data marketplace. Vertically integrated — no third-party API assemblies.
01
Trial design
Non-inferiority, superiority, equivalence, and adaptive engines with statistical optimization.
02
Enrollment intelligence
Predictive enrollment modeling, site scoring, dropout risk analysis.
03
Regulatory copilot
Automated IND/NDA/BLA gap analysis across FDA, EMA, and ICH.
04
Adaptive analytics
Biomarker-guided interim analyses with real-time decision support.
05
Data marketplace
Tokenized datasets with provenance, fractional licensing, institutional access.
06
Trial-to-token
The first tokenized clinical data exchange with on-chain provenance.
07
Autonomous agents
AI agents that monitor trial health and optimize operations around the clock.
08
Adaptive intelligence
Real-time biomarker analysis that triggers protocol adaptations.
Why this exists
Every day of delay is a day patients wait. Every dollar wasted is diverted from discovery.
Flagship
Clinical Trial Operating System.
CTOS sits above the engines and decides what to do next — unifying protocol intelligence, adaptive execution, and a tokenized data marketplace into a single governing layer for the trial lifecycle.
Decision states
- Stop — efficacy achieved
- Stop — futility threshold
- Adapt — enrichment needed
- Continue — monitor
Get started
See it on a real trial.
30-minute walkthrough. Bring an active trial; we'll walk through what CTOS would surface.